Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Tamim Alsuliman; Clotilde Aubrun; Jacques Olivier Bay; Yves Beguin; Camille Bigenwald; Eolia Brissot; Yves Chalandon; Patrice Chevallier; Simona Pagliuca; Léonardo Magro; Micha Srour

doi:10.1016/j.bulcan.2024.02.013

Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Tamim Alsuliman, Clotilde Aubrun, Jacques Olivier Bay, Yves Beguin, Camille Bigenwald, Eolia Brissot, Yves Chalandon, Patrice Chevallier, Simona Pagliuca, Léonardo Magro, Micha Srour

Research output: Contribution to journal › Article › peer-review

Abstract

Chimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.

Translated title of the contribution	Toxicités hématologiques après CAR-T cells, recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Original language	English
Journal	Bulletin du Cancer
DOIs	https://doi.org/10.1016/j.bulcan.2024.02.013
Publication status	Accepted/In press - 1 Jan 2024

Keywords

Hematological toxicities
Post-CAR-T cells
Recommendations
SFGM-TC

Access to Document

10.1016/j.bulcan.2024.02.013

Cite this

Alsuliman, T., Aubrun, C., Bay, J. O., Beguin, Y., Bigenwald, C., Brissot, E., Chalandon, Y., Chevallier, P., Pagliuca, S., Magro, L., & Srour, M. (Accepted/In press). Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2024.02.013

@article{6dc753f62f134b91bc4d7afbc2247b4a,

title = "Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)",

abstract = "Chimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.",

keywords = "Hematological toxicities, Post-CAR-T cells, Recommendations, SFGM-TC",

author = "Tamim Alsuliman and Clotilde Aubrun and Bay, {Jacques Olivier} and Yves Beguin and Camille Bigenwald and Eolia Brissot and Yves Chalandon and Patrice Chevallier and Simona Pagliuca and L{\'e}onardo Magro and Micha Srour",

note = "Publisher Copyright: {\textcopyright} 2024 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/j.bulcan.2024.02.013",

language = "English",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Hematological toxicities post-CAR-T cells

T2 - Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

AU - Alsuliman, Tamim

AU - Aubrun, Clotilde

AU - Bay, Jacques Olivier

AU - Beguin, Yves

AU - Bigenwald, Camille

AU - Brissot, Eolia

AU - Chalandon, Yves

AU - Chevallier, Patrice

AU - Pagliuca, Simona

AU - Magro, Léonardo

AU - Srour, Micha

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Chimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.

AB - Chimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.

KW - Hematological toxicities

KW - Post-CAR-T cells

KW - Recommendations

KW - SFGM-TC

UR - http://www.scopus.com/inward/record.url?scp=85190494250&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2024.02.013

DO - 10.1016/j.bulcan.2024.02.013

M3 - Article

AN - SCOPUS:85190494250

SN - 0007-4551

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -

Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Abstract

Keywords

Access to Document

Other files and links

Cite this